[Special Stock] AimedBio Achieves "TtaTtaBul" on First Day of KOSDAQ Listing

AimedBio achieved a "Tta-Tta-Ble" (quadruple increase from the IPO price) on its first day of KOSDAQ listing.

The KOSDAQ Market Division of Korea Exchange held a listing ceremony for AimedBio, which develops antibodies and antibody-drug conjugates based on patient genomics and patient-derived model platforms, at 9 a.m. on the 4th at the Seoul headquarters PR center.

As of 9:13 a.m. on December 4, AimedBio was trading at 44,000 won, up 33,000 won (300%) from its IPO price of 11,000 won.

During the institutional investor demand forecast held from November 12 to 18, AimedBio recorded a competition rate of 672 to 1, resulting in the IPO price being set at the upper end of the desired range (9,000 to 11,000 won), at 11,000 won. In the general subscription held from November 21 to 24, the competition rate was 1,736.8 to 1. The subscription deposit amounted to approximately 15.3552 trillion won, the largest among KOSDAQ IPO companies this year.

Spun off from Samsung Medical Center in 2018, AimedBio is a biotech company developing antibody-based ADC (antibody-drug conjugate) new drugs. ADC is a next-generation anticancer drug technology designed to maximize therapeutic effects by selectively delivering anticancer agents to cancer cells through antibodies, while reducing side effects compared to conventional chemotherapy drugs.